Mankind Pharma Announces Unaudited Financial Results for Quarter and Half Year Ended September 30, 2025
Mankind Pharma announces unaudited financial results for the quarter and half year ended September 30, 2025, with consolidated revenue of ₹3,697.16 crore and profit before tax of ₹624.02 crore for the quarter.
The financial results provide insights into the company's performance, which is relevant to investors and stakeholders. However, without additional context or comparison to previous periods, the impact is moderate.
The announcement is a routine disclosure of financial results, presenting both consolidated and standalone figures without expressing a particular positive or negative outlook.
* Mankind Pharma Limited has announced the unaudited financial results for the quarter and half year ended September 30, 2025. * The results were published in the "Financial Express" and "Jansatta" newspapers on November 7, 2025. * Consolidated results for the quarter ended September 30, 2025: * Revenue from operations: ₹3,697.16 crore * Profit before tax: ₹624.02 crore * Profit after tax: ₹520.18 crore * Consolidated results for the six months ended September 30, 2025: * Revenue from operations: ₹7,267.51 crore * Profit before tax: ₹1,164.51 crore * Profit after tax: ₹964.80 crore * Standalone results for the quarter ended September 30, 2025: * Revenue from operations: ₹2,608.78 crore * Profit before tax: ₹524.63 crore * Profit after tax: ₹458.90 crore * Standalone results for the six months ended September 30, 2025: * Revenue from operations: ₹5,150.14 crore * Profit before tax: ₹1,018.29 crore * Profit after tax: ₹871.66 crore
What to do with a filing like this
Mankind Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mankind Pharma Limited. Read the original for the full detail.